1. Ireland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

AVDL
Avadel Pharmaceuticals plcUS flagNASDAQ Global Market
21.64
USD
- -
- -
2.12BMarket Cap
Avadel Pharmaceuticals plc
AVDL
(NASDAQ Global Market)

Recent

price

21.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
1.74
1.52
1.32
0.3
0.16
0.41
4.26
3.64
4.28
2.77
1.58
0.42
- -
- -
0.35
1.78
2.57
Revenue per Share
-0.47
-0.37
-0.36
-0.13
-1.69
-2.36
1.03
-1
1.69
-2.55
-0.89
0.13
-1.32
-2.29
-2
-0.51
- -
Basic EPS, GAAP
0.27
-0.37
-0.5
-0.97
-0.85
-0.34
2.04
0.43
-0.92
-2.76
-1.03
-0.92
-1.32
-1.18
-1.6
-0.49
0.36
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-6.94
-7.25
-7.53
-7.53
-9.11
-8.68
-6.71
-7.74
-6.48
-9.58
-10.45
-7.24
-7.64
-9.73
-9.29
-8.34
-8.15
Book Value per Share
1.85
1.49
1.21
-1.18
-2.68
-0.61
0.86
0.02
-0.62
-0.46
-1.3
2.74
1.05
-0.63
0.88
0.6
0.84
Tangible Book Value per Share
24
24
25
25
25
36
41
41
40
37
37
53
59
60
80
95
97
Basic Weighted Avg Shares
42
37
33
8
4
15
173
150
173
103
59
22
- -
- -
28
169
249
Sales/Revenue/Turnover
-27.9
-26.53
-29.4
-286.4
-611.75
-221.39
58.79
29.5
35.21
-58.64
-28.42
-164.15
- -
- -
-492.97
-25.07
1.82
Operating Margin (%)
6
5
3
3
3
14
13
14
5
7
2
2
1
1
2
3
4
Depreciation Expense
-11
-9
-9
-3
-43
-85
42
-41
68
-95
-33
7
-77
-137
-160
-49
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
46.21
- -
26.32
- -
- -
- -
- -
- -
- -
- -
62.96
Effective Tax Rate (%)
-27.16
-24.2
-26.91
-42.85
-1,027.16
-570.74
24.16
-27.47
39.41
-92.29
-56.11
31.47
- -
- -
-573.17
-28.87
-0.11
Profit Margin (%)
44
26
18
11
-7
41
121
119
37
86
46
248
171
45
97
85
110
Working Capital
3
2
2
33
66
1
1
1
- -
116
124
130
144
92
2
1
2
LT Debt
45
36
30
31
-10
25
69
42
86
3
-29
162
78
-21
88
74
98
Total Equity
- -
- -
- -
- -
- -
- -
97.94
- -
68.97
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-14.37
- -
-23.79
- -
- -
- -
- -
- -
- -
- -
-19.93
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
97
97
Market Capitalization
755
854
1,477

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
139
159
172
Cash, Cash Equivalents & STI
66
82
92
Accounts Receivable, Net
42
41
42
Inventories
20
23
24
Total Current Liabilities
51
57
62
Payables & Accruals
30
32
31
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-237.04%
-273.06%
-15.83%
Free Cash Flow
-94.74%
18.99%
-63.5%
Net Income, GAAP
-221.44%
-259.32%
-69.53%
Sales/Revenue/Turnover
- -
- -
504.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
1
7
19
28
2024
27
42
50
50
169
2025
53
68
77
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.48
-0.83
-0.41
- -
-2
2024
-0.3
-0.14
-0.03
-0.05
-0.51
2025
-0.05
0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
Nippon Chemiphar Co., Ltd. (4539.T)
Harvest Health & Recreation Inc. (HRVSF)
Dakshidin Corporation, Inc. (DKSC)
OWC Pharmaceutical Research Corp. (OWCP)
Speakeasy Cannabis Club Ltd. (EASY.CN)
Business
Avadel Pharmaceuticals plc is a specialty pharmaceutical company focused on the development and commercialization of innovative products primarily for central nervous system disorders and sleep-related conditions. The company's core products and services include prescription pharmaceuticals and therapeutics, notably in sleep medicine with its proprietary product Xyrem (sodium oxybate) used for the treatment of narcolepsy and other sleep disorders; Avadel also develops pipeline candidates in areas such as migraine and pain management. Avadel operates globally, with a strong presence in the United States, Europe, and other international markets. Founded in 2015 and headquartered in Dublin, Ireland, Avadel Pharmaceuticals plc specializes in developing user-friendly drug delivery systems and oral controlled-release formulations. In the past two years, Avadel Pharmaceuticals has undergone significant strategic changes including the recent launch of new formulations and expansion of its product pipeline targeting central nervous system disorders. The company has entered into strategic partnerships to enhance commercialization and market reach, and it has focused on broadening its sleep disorder portfolio with innovative products. Avadel continues to invest in research and development initiatives to strengthen its pipeline, targeting unmet medical needs beyond its existing products. These moves exemplify Avadel’s commitment to growing its footprint in specialty pharmaceuticals through innovation and collaboration. Operating within the pharmaceutical industry, Avadel targets healthcare providers, patients with chronic conditions like narcolepsy and migraine, and pharmaceutical distributors across multiple regions. The company is publicly traded under the ticker AVDL and positions itself as a leader in specialty pharmaceutical solutions focused on improving patient outcomes with innovative drug delivery technologies and novel therapeutic agents. Avadel Pharmaceuticals plc’s continuous efforts reflect its strategic priority to enhance patient care through differentiated pharmaceutical products and expand its market presence globally.

Company News

APIChat